New Hope for Dementia

Vivid Genomics is developing tools to identify this variation to support and improve clinical trial design and analysis.

Precision medicine has become the standard approach in Oncology and cancer drug development over the last ~20 years, and with the availability of large neurogenetic data sets, proprietary samples, and new sophisticated AI and machine learning tools, Vivid Genomics is enabling precision medicine for neurodegenerative disease.We believe a large part of the problem is that there is a significant amount of variation between patients; they often have multiple forms of dementia, differing rates of disease progression, or different subtypes of disease.  All of these factors can bias or negatively impact clinical trial outcomes, and yet this variation is challenging to characterize.